Armata Pharmaceuticals, Inc., a biotechnology company dedicated to developing bacteriophage therapeutics for challenging bacterial infections, has announced the receipt of an additional $4.65 million in non-dilutive funding from the U.S. Department of Defense. This funding is part of a larger award currently totaling $26.2 million, received through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command, aimed at supporting the clinical development of Armata's phage candidate, AP-SA02. The funding will facilitate the Phase 2a study closeout activities and preparations for an end-of-phase 2 meeting with the U.S. Food and Drug Administration. This continued support underscores the DoD's commitment to advancing AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia.